Description
Overview
CJC-1295 Without DAC + Ipamorelin is a research-grade blend combining two peptides with complementary mechanisms of action in growth hormone axis research. CJC-1295 Without DAC (also known as Modified GRF 1–29) is a GHRH analog that stimulates GH release through the GHRH receptor, while Ipamorelin is a highly selective growth hormone secretagogue receptor (GHS-R/ghrelin receptor) agonist. Together, they provide researchers with a dual-pathway approach to studying GH secretion dynamics.
Blend Composition
- CJC-1295 Without DAC (5mg) — Modified GRF(1–29) with amino acid substitutions at positions 2, 8, 15, and 27 for enhanced stability. GHRH receptor agonist
- Ipamorelin (5mg) — Selective pentapeptide GHS-R agonist. Unlike other GH secretagogues, does not significantly affect ACTH, cortisol, or prolactin in research models
Research Applications
This blend has been formulated for research protocols involving:
- Dual-pathway GH secretion studies (GHRH + GHS-R co-stimulation)
- GH pulsatility and amplitude modulation in preclinical models
- IGF-1 axis activation and downstream signaling research
- Comparative secretagogue studies evaluating synergistic versus additive effects
- Somatotroph receptor cross-talk and signal integration research
- Selectivity profiling of GHS-R agonists on neuroendocrine parameters
Specifications
- Purity: ≥99% per component (HPLC verified)
- Form: Lyophilized powder blend
- Total Content: 10mg combined (5mg + 5mg)
- Solubility: Soluble in bacteriostatic water or sterile water
- Storage: Store at -20°C for long-term stability. Reconstituted solutions should be refrigerated at 2–8°C
Handling
This product is intended for laboratory research only. Reconstitute with bacteriostatic water for research applications. Use aseptic technique during preparation. Refer to published literature for appropriate research concentrations.
For research and laboratory use only. Not for human consumption. Sold exclusively to qualified researchers and licensed institutions.
